Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 8/20 | 0.46 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | LPL | P06858 | 3/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758403 | 0.82 | TNFRSF1A (0.43) | PDGFRBKDRLPLLIPGERN1 | |
| SCHEMBL15481254 | 0.81 | LIPG (0.60) | PDGFRBKDRLPLLIPGAPP | |
| SCHEMBL29631781 | 0.81 | LIPG (0.60) | PDGFRBKDRLPLLIPGAPP | |
| SCHEMBL22214718 | 0.78 | LIPG (0.50) | PDGFRBKDRLPLLIPGAPP | |
| SCHEMBL29871636 | 0.77 | LIPG (0.60) | PDGFRBKDRLPLLIPGHSD17B1 | |
| SCHEMBL759136 | 0.77 | LIPG (0.60) | PDGFRBKDRLPLLIPGHSD17B1 | |
| SCHEMBL758354 | 0.77 | MAPKAPK2 (0.48) | PDGFRBKDRLPLLIPG | |
| SCHEMBL18015333 | 0.75 | KDM1A (0.48) | PDGFRBKDRLPLLIPGSNCA | |
| SCHEMBL1587918 | 0.74 | APP (0.65) | APPERN1HSD17B1HSD17B2 | |
| SCHEMBL21541874 | 0.73 | LIPG (0.55) | PDGFRBKDRLPLLIPGAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | PDGFRB 2312/4885KDR 3628/4885LPL 3658/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | PDGFRB 2312/4885KDR 3628/4885LPL 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.